Search Results
Your search for ,Any matches 8114 pages
Showing 5451 - 5500Study Finds EXITS Gene Mutations May Contribute to Cancer Sex Bias
According to Surveillance, Epidemiology, and end Results (SEER) data from 2008 to 2012, American males have an excess risk of 20.4% of developing any cancer compared with females, and there is a ≥ 2:1 male predominance for some individual cancers. This excess risk results in approximately...
Anti–PD-1 Contenders in Advanced Urothelial Cancer
Immunotherapy with anti–PD-1 (programmed cell death protein 1) and anti–PD-L1 (programmed cell death ligand 1) agents continues to advance in metastatic urothelial cancer, with positive showings in two clinical trials presented at the 2016 European Society for Medical Oncology (ESMO) Congress. The...
Androgen Receptor Antagonists May Meet ‘Unmet Need’ in Triple-Negative Breast Cancer
Although there are no androgen receptor antagonists currently approved for the treatment of breast cancer, clinical trials indicate that these agents benefit some patients with triple-negative breast cancer, Tiffany A. Traina, MD, told participants at the 18th Annual Lynn Sage Breast Cancer...
Phase III Trial Shows Ado-Trastuzumab Emtansine Noninferior to Trastuzumab/Taxane in HER2-Positive Breast Cancer
In the phase III MARIANNE trial reported in the Journal of Clinical Oncology, Perez et al found that ado-trastuzumab emtansine (formerly known as T-DM1; Kadcyla) was associated with noninferior progression-free survival compared with trastuzumab (Herceptin) plus taxane in patients with...
CancerLinQ™ Platform Hits Milestone of Having More Than 1 Million Patient Records in System
CancerLinQ LLC, a wholly owned nonprofit of ASCO, has announced that more than 1 million patient records are now in the CancerLinQ™ platform. In addition, 70 practices have signed agreements to participate in CancerLinQ™, representing more than 1,500 oncologists. “We are excited to reach this...
Apply for ASCO Health Policy Fellowship to Improve Skills Needed to Shape Cancer Policy
ASCO is now accepting applications for its prestigious Health Policy Fellowship, a 1-year fellowship opportunity designed to give early-career oncologists the unique skills necessary to monitor and shape the regulatory and legislative policies that directly affect the practice environment and...
Updated ASTRO Guideline Expands Pool of Suitable Candidates for Accelerated Partial-Breast Irradiation
On November 17, the American Society for Radiation Oncology (ASTRO) issued an updated clinical practice statement for accelerated partial-breast irradiation for early-stage breast cancer. The updated guideline reflects recent evidence that greater numbers of patients can benefit from accelerated...
Adding Olaratumab to Doxorubicin Increases Overall Survival in Advanced Soft-Tissue Sarcoma
As reported by William D. Tap, MD, of Memorial Sloan Kettering Cancer Center, and colleagues in The Lancet, the addition of the anti-PDGFRα (platelet-derived growth factor receptor alpha) antibody olaratumab to doxorubicin resulted in prolonged progression-free and overall survival in phase II...
Expert Point of View: Paul Baas, MD, PhD
Invited discussant Paul Baas, MD, PhD, of The Netherlands Cancer Institute, Amsterdam, first commented on the need for measures to improve outcomes in early-stage non–small cell lung cancer (NSCLC). “Even in stage I patients, we still have a failure rate of 30% to 40% at 5 years, and that...
Neoadjuvant Nivolumab Appears Safe and Feasible in Lung Cancer
Neoadjuvant immunotherapy with the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) is safe and feasible in early-stage non–small cell lung cancer (NSCLC). The results come from the first report of PD-1 blockade prior to surgery in this tumor, according to Patrick Forde, MD, of...
The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research
Earlier this year, Sean Parker, the cofounder of the music streaming service Napster and an early president of Facebook, joined a growing list of entrepreneurs who are committing large portions of their wealth to funding cancer research. In April, Mr. Parker announced he was donating $250 million...
Neoadjuvant Chemotherapy in High-Risk Soft-Tissue Sarcoma: A New Standard?
For the first time, a randomized trial has provided good evidence to support the use of neoadjuvant chemotherapy for treatment of high-risk soft-tissue sarcoma of the extremities or trunk wall.1 But the findings of the study were surprising, because neoadjuvant chemotherapy with one-size-fits-all...
Phase III Trial Shows No Survival Benefit of Adding First-Line IMA901 Vaccine to Sunitinib in Advanced Renal Cell Carcinoma
In the phase III IMPRINT trial reported in The Lancet Oncology, Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, and colleagues found no overall survival benefit of adding the multipeptide cancer vaccine IMA901 to sunitinib (Sutent) in the first-line treatment of locally...
AMA Statement on the Future of Health-Care Reform
“The AMA House of Delegates, reflecting more than 170 state and specialty medical societies from across the country, today reaffirmed its commitment to health care reform that improves access to care for all patients. “Using a comprehensive policy framework that has been refined over the past 2...
‘Breakthrough’ in Recurrent Ovarian Cancer: Niraparib Extends Progression-Free Survival in Platinum-Sensitive Disease
A landmark study showed that the investigational PARP (poly ADP-ribose polymerase) 1/2 inhibitor niraparib, when used as maintenance therapy, significantly improves the outcome of platinum-sensitive recurrent ovarian cancer. Specifically, niraparib significantly prolonged progression-free survival ...
Recent Progress and Concepts in Pancreatic Cancer
November is National Pancreatic Cancer Awareness Month, the impetus for this article. Pancreatic cancer is a huge health challenge. It's the eighth most common cancer in the United States and the fourth most common cause of cancer deaths but is expected to become the second most common cause of...
Pembrolizumab Improves Outcomes vs Platinum-Based Chemotherapy in Advanced PD-L1–Positive NSCLC
In the phase III KEYNOTE-024 trial reported in The New England Journal of Medicine by Martin Reck, MD, PhD, of the German Center of Lung Research, Grosshansdorf, and colleagues, pembrolizumab (Keytruda) significantly improved progression-free and overall survival vs platinum-based chemotherapy in...
Phase III Trial Shows Improved PFS With Addition of Palbociclib to Letrozole in ER-Positive, HER2-Negative Breast Cancer
In the phase III PALOMA-2 trial reported in The New England Journal of Medicine, Finn et al found that the addition of palbociclib (Ibrance) to letrozole significantly improved progression-free survival in postmenopausal women with previously untreated advanced estrogen receptor–positive,...
New Study Links Obesity, Starting at Adolescence, to Endometrial Cancer Among Women Not Using Hormone Therapy
While it is well established that obesity is closely linked to endometrial cancer risk, most past findings have only looked at risk in relation to one measure of body size at a time. In a new study led by the Cancer Prevention Institute of California, published by Horn-Ross et al in Cancer Causes...
Study Describes Genetic Model of Pro-B ALL
After nearly 2 decades of unsuccessful attempts, researchers from the University of Chicago Medicine and the Cincinnati Children's Hospital Medical Center have created the first mouse model for the most common form of infant leukemia. Their discovery, reported by Lin et al in Cancer Cell, could...
SITC 2016: Immune Checkpoint Inhibitors Shrink Tumors in Some Patients With Metastatic Bladder Cancer
Combination immunotherapy is producing response rates ranging from 26% to 38% among patients with metastatic bladder cancer in the early stages of a three-arm clinical trial presented at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland. “Until...
No Benefit Reported With Addition of Palifosfamide to Doxorubicin in Metastatic Soft-Tissue Sarcoma
In the phase III PICASSO III trial reported in the Journal of Clinical Oncology, Ryan et al found that adding palifosfamide to doxorubicin did not prolong progression-free survival among patients with metastatic soft-tissue sarcoma. Palifosfamide is the active metabolite of ifosfamide. In the...
Living With Metastatic Breast Cancer Is Like Walking a Tightrope
I’ve always had fibrocystic breasts and was steadfast in performing monthly breast self-exams, so I could become familiar with the terrain of my breasts and spot any subtle changes. So, in November 2002, when I felt something in my left breast that seemed different from my usual lumps, I made a...
Expect Questions About Medical Marijuana
“Whether or not individual professionals support the clinical use of herbal cannabis, all clinicians will encounter patients who elect to use it and therefore need to be prepared to advise them on cannabis-related clinical issues despite limited evidence to guide care,” according to a recently...
The Smartest Guys in the Room
The smartest guys in the room were never from the big energy companies, and they’re not running hedge funds on Wall Street or building the next Facebook. For me, the smartest guys in the room are the selfless men and women who’ve transformed cancer from what was all too often a death sentence to...
Enrollment Completed for Phase III ECHELON-2 Clinical Trial Evaluating Front-Line Brentuximab Vedotin in Mature T-Cell Lymphoma
Seattle Genetics, Inc, and Takeda Pharmaceutical Company Limited have announced completion of patient enrollment in the ECHELON-2 clinical trial. ECHELON-2 is a global phase III randomized trial evaluating brentuximab vedotin (Adcetris) as part of a front-line combination chemotherapy regimen in...
Olaratumab in Soft-Tissue Sarcoma
On October 19, 2016, the platelet-derived growth factor receptor alpha (PDGFR-α)-blocking antibody olaratumab (Lartruvo) was granted accelerated approval in combination with doxorubicin for the treatment of soft-tissue sarcoma not amenable to curative treatment with radiotherapy or surgery and...
No Advantage to Adding Seribantumab to Paclitaxel in Platinum-Resistant/Refractory Ovarian Cancer, but Subgroup May Benefit
In a phase II study reported in the Journal of Clinical Oncology, Liu et al found no progression-free survival benefit of adding the anti-HER3 (ErbB3) antibody seribantumab to paclitaxel in unselected patients with advanced platinum-resistant or -refractory ovarian cancer. However, exploratory...
Meeting the Needs of Older Adults With Cancer
I have served as a patient advocate in many different ways since I was diagnosed with breast cancer in October 2000. For many years, my advocacy was focused on issues related to breast cancer. Since 2012, I have also been engaged in identifying and meeting the needs of the rapidly growing...
Talking to Children With Cancer: Sometimes Less Is More
I still remember the day I met Kensie. It was Valentine’s Day. I had sneaked out of the hospital to get my wife a Valentine’s Day card, taking my place among scores of other husbands and boyfriends in front of the rapidly emptying rack of cards. As I started browsing, my beeper sounded. It was the ...
Forging Collaboration Between Children’s and Adult Oncology Groups in Designing Trials for Adolescents and Young Adults
Nonrhabdomyosarcoma soft-tissue sarcomas account for about 5% of all childhood malignancies and are also diagnosed in adolescents and young adults, as well as in older adults, and can require different approaches to treatment based on a patient’s age and stage of disease. These sarcomas comprise...
Interviews With ASCO’s President-Elect Candidates
ASCO Connection: Why do you want to serve as ASCO President? Monica Bertagnolli: Serving as ASCO President is a tremendous personal honor for anyone in the field of oncology. Much more importantly, it is an opportunity to make a meaningful difference by providing a strong voice in the health-care ...
Atezolizumab in Previously Treated Metastatic NSCLC
On October 18, 2016, the anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab (Tecentriq) was approved for the treatment of metastatic non–small cell lung cancer (NSCLC) progressing during or following platinum-containing chemotherapy.1,2 Patients with epidermal growth factor receptor ...
CancerLinQ™ Platform Hits Milestone of Having More Than 1 Million Patient Records in System
CancerLinQ LLC, a wholly owned nonprofit of ASCO, announced on October 20, 2016, that more than 1 million patient records are now in the CancerLinQ™ platform. In addition, 70 practices have signed agreements to participate in CancerLinQ, representing more than 1,500 oncologists. “We are excited to...
As More Biosimilars Move Toward U.S. Market, Questions Remain About Cost Savings and Uptake by Physicians and Patients
The U.S. Food and Drug Administration (FDA) approved its first biosimilar drug, filgrastim-sndz (Zarxio), in 2015, allowing it to compete with the granulocyte colony-stimulating factor filgrastim (Neupogen) to treat neutropenia in chemotherapy patients. So far, filgrastim-sndz is the only...
Study Looks for Optimal Dosing of Single-Agent Ipilimumab in Metastatic Melanoma
There has been debate as to the optimal dose of single-agent ipilimumab (Yervoy) in metastatic melanoma. A phase III study presented at the 2016 European Society for Medical Oncology (ESMO) Congress—the first to directly compare these doses—concluded that 10 mg/kg is more effective, but also more...
Small Study Tests Dual Checkpoint Blockade in High-Risk Stage III Melanoma
As neoadjuvant or adjuvant therapy for stage III melanoma patients with palpable disease, the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) was shown to be a promising, though also toxic, combination in a phase Ib study reported at the 2016 European Society for Medical Oncology (ESMO) ...
Is Observation Without Surgery a Viable Strategy for Managing Ductal Carcinoma in Situ?
In a spirited debate, abounding with citations of clinical trials and other evidence, but not without humor and mutual respect, E. Shelley Hwang, MD, MPH, and Armando E. Giuliano, MD, reviewed the data and their clinical experience managing ductal carcinoma in situ and reached opposite...
1 in 6 Women Diagnosed With Breast Cancer Have a Symptom Other Than a Lump
Around one in six women (17%) diagnosed with breast cancer go to their doctor with a symptom other than a lump—the most commonly reported breast cancer symptom—according to new research presented by Koo et al at the 2016 National Cancer Research Institute (NCRI) Cancer Conference in...
Preliminary Data Indicate Potential Role for Dabrafenib as Part of Therapy for Pediatric Low-Grade Gliomas With BRAF V600 Mutation
About 10% of children with low-grade gliomas have the BRAF V600E mutation, and preliminary studies suggest that the BRAF inhibitor dabrafenib (Tafinlar) may play an important role in treating this group of patients. A phase I/II trial presented at the 2016 European Society for Medical Oncology...
Pembrolizumab, but Not Nivolumab, Improves Outcomes in Front-Line Setting for PD-L1–Positive Advanced NSCLC
Checkpoint inhibitors have revolutionized the treatment of advanced non–small cell lung cancer (NSCLC), but evidence of their benefit was restricted to the second-line setting. However, early-phase trials with both pembrolizumab (Keytruda) and nivolumab (Opdivo) demonstrated favorable results in...
Multiple Genetic Mutational Signatures Associated With Smoking
Scientists have measured the genetic damage caused by smoking in different organs of the body and identified several different mechanisms by which tobacco smoking causes mutations in DNA. Researchers at the Wellcome Trust Sanger Institute, the Los Alamos National Laboratory, and their collaborators ...
Pembrolizumab Plus Chemotherapy Improves Outcomes Over Chemotherapy Alone in Advanced NSCLC
Combining immunotherapy with a standard chemotherapy doublet appears to be an attractive option for the front-line treatment of advanced nonsquamous non–small cell lung cancer (NSCLC), according to the results of a phase II study presented at the 2016 European Society for Medical Oncology (ESMO)...
Phase III Study of Sunitinib Is First to Show Benefit in Adjuvant Setting for Treatment of Renal Cell Carcinoma
Sunitinib (Sutent) improved disease-free survival by more than 1 year when used as adjuvant treatment for high-risk locoregional renal cell carcinoma following nephrectomy, but with the cost of toxicity. S-TRAC is the first phase III trial showing a benefit for adjuvant therapy in renal cell...
New Data Suggest Changes Needed to Guidelines for Determining Prognosis in Patients With Thyroid Cancer
A study from the Duke Cancer Institute (DCI) has found a lack of statistical evidence to support the current practice of treating thyroid cancer patients under age 45 differently from those 45 and older. The study, published recently by Adam et al in the Journal of Clinical Oncology,...
How ASCO Is Preparing Members for MACRA
On October 14, 2016, the Centers for Medicare & Medicaid Services (CMS) announced its final policy on what physicians need to do to begin implementing the Quality Payment Program outlined in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The Quality Payment Program is a...
Expert Point of View: Corey J. Langer, MD
Corey J. Langer, MD, Director of Thoracic Oncology and Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, discussed the OAK study with The ASCO Post. Robust Data “In some ways, the OAK data are some of the most robust we have seen in the second-line setting. For ...
Notable Gains in Survival Achieved With Atezolizumab in Non–Small Cell Lung Cancer
The programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab (Tecentriq) significantly improved overall survival, compared to docetaxel, in previously treated, advanced non–small cell lung cancer (NSCLC), according to preliminary results of the phase III OAK study. The findings are the first...
Study Raises Concerns About Timely Follow-up to Positive Mammogram for the Uninsured
A study by University of North Carolina (UNC) Lineberger Comprehensive Cancer Center researchers has found that younger, uninsured women in North Carolina had higher odds of missing a 60-day window for getting follow-up after an abnormal mammogram, even though research underscores the importance of ...
Ribociclib Granted FDA Priority Review for First-Line Treatment of Hormone Receptor–Positive/HER2-Negative Advanced Breast Cancer
On November 1, the U.S. Food and Drug Administration (FDA) accepted a New Drug Application (NDA) for filing and granted Priority Review for ribociclib (LEE011) as first-line treatment of postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2...
